About ManagedLab

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium dolemue launti totam aperiam, eaque ipsa quae abillo. Invente veriatis et quasi.

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

Posted by |2020-08-10T03:30:05-07:00August 7th, 2020|

The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home. Risdiplam (Evrysdi) is a liquid medicine intended for daily use that was developed by Roche subsidiary Genentech in partnership with the SMA Foundation and South Plainfield, NJ-based PTC Therapeutics (NASDAQ: PTCT). Regulators OK’d the drug, intended for daily […]

GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod

Posted by |2020-08-06T15:49:09-07:00August 6th, 2020|

Patients with advanced multiple myeloma have a new treatment option with the FDA’s approval of a GlaxoSmithKline drug that targets B-cell maturation antigen, a protein found on the surface of cancerous plasma cells. The agency OK’d the London-based pharma giant’s cancer drug, belantamab mafodotin (Blenrep), based on the results of a study in which patients […]

MeiraGTx Names Immunovant’s Zeldin as Its Chief Medical Officer

Posted by |2020-08-05T19:38:29-07:00August 5th, 2020|

Robert Zeldin has joined gene therapy developer MeiraGTx as its chief medical officer. Most recently he held the same role at Immunovant (NASDAQ: IMVT). Prior Zeldin served as CMO at Acceleron Pharma (NASDAQ: XLRN) and at Ablynx. His experience also includes time at Stallergenes, Novartis (NYSE: NVS), and Merck, as well as a stint with […]

Black Diamond Makes Fang Ni’s Chief Business Officer Job Permanent

Posted by |2020-08-04T18:33:00-07:00August 4th, 2020|

Black Diamond Therapeutics (NASDAQ: BDTX) has appointed Fang Ni to serve as its chief business officer. Ni has held the role on an interim basis since the company emerged from stealth in late 2018. Ni was most recently a principal and member of the investment team at Versant Ventures, which incubated Black Diamond before launching it […]

Legend Biotech CEO Xu Resigns, GenScript’s Zhang Named Successor

Posted by |2020-08-03T13:27:28-07:00August 3rd, 2020|

Yuan Xu, the CEO of Legend Biotech (NASDAQ: LEGN) for the past two years, has resigned for “personal reasons,” the company announced Sunday. No other details were given. She has also stepped down from the Somerset, NJ, company’s board of directors. Frank Zhang, chairman of Legend’s board and CEO of GenScript, the biotech’s largest shareholder, […]

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

Posted by |2020-08-03T03:30:20-07:00July 31st, 2020|

Kymera Therapeutics has a pipeline of preclinical drug candidates that use an experimental approach to get rid of disease-causing proteins and it’s now looking to tap the public markets to finance tests of the technology in humans. In paperwork submitted to the Securities and Exchange Commission on Friday, Kymera set a $100 million goal for […]

Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D

Posted by |2020-07-30T16:34:27-07:00July 30th, 2020|

Another biopharma has signed up to use Sangamo Therapeutics’ gene editing technology to develop therapies that can address disease by heightening or depressing a gene’s activity level. Sangamo on Thursday announced that Novartis (NYSE: NVS) had agreed to shell out $75 million up front to leverage the biotech’s genome regulation technology to treat certain neurodevelopmental […]

Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort

Posted by |2020-07-29T16:00:09-07:00July 29th, 2020|

Public investors are betting big on biotechs, and Inhibrx is looking to capitalize on the industry’s recent resurgence of initial public offerings. The La Jolla, CA-based company, which is developing drugs for cancer and a rare respiratory disease, has again applied for a listing on the Nasdaq, a filing that comes more than a year […]

Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test

Posted by |2020-07-28T08:11:52-07:00July 28th, 2020|

Pfizer and BioNTech’s COVID-19 vaccine research started with multiple approaches—four shots on the messenger RNA goal. The partners have narrowed their choices to one for pivotal testing, and that candidate takes the same tack as other companies trying to address the novel coronavirus. BNT162b2, the vaccine candidate that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) […]

Telehealth Firm AristaMD Adds $24M to Link Primary Docs With Specialists

Posted by |2020-07-27T18:50:46-07:00July 27th, 2020|

Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors. The San Diego-based telehealth company’s software links primary care physicians and medical specialists through virtual consultations, communication that is intended to reduce healthcare costs by slimming down the number of referrals made […]

Clinical Trial Diversity Isn’t Just a Moral Issue–It’s a Scientific Imperative

Posted by |2020-07-27T02:00:22-07:00July 27th, 2020|

The lack of diversity in clinical trials is a serious problem that’s persisted for decades. Black Americans—who make up 20 percent of US multiple myeloma patients and are twice as likely to be diagnosed—have only accounted for 4.5 percent of participants in multiple myeloma trials since 2003. Asian Americans—who make up nearly 6 percent of […]

Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma

Posted by |2020-07-26T03:30:09-07:00July 24th, 2020|

The FDA on Friday approved a Gilead Sciences drug developed for treating mantle cell lymphoma, paving the way for the company to commercialize its second cancer cell therapy. Approval for the drug, brexucabtagene autoleucel (Tecartus), covers patients whose cancer has relapsed or has not responded to earlier treatments. Gilead (NASDAQ: GILD) added the therapy to […]
Load More Posts